thought leadership
Manufacturers must adapt to growing GLP-1 and GIP/GLP-1 receptor agonists markets
By Mariia Salova, Amy Schroeder | July 9, 2025
Table 1. Differentiation in GLP-1 products
*Weight-related comorbidities may include but are not limited to hypertension, dyslipidemia, CVD, sleep apnea, and T2D. CKD: Chronic Kidney Disease; CVD: Cardiovascular Disease
GLP and GIP/GLP-1 RAs had 88% on-label use and 12% off-label use (Figure 1), which was consistent with uses at the brand level. In recent years, off-label use for weight loss has contributed to GLP-1 RAs shortages, limiting access for patients with diabetes.
Figure 1. On- and off-label use of GLP-1 and GIP/GLP-1 RAs*

*GLP-1 and GIP/GLP-1 RAs include: Bydureon, Byetta, Victoza, Ozempic, Rybelsus, Adlyxin, Saxenda, Wegovy, Zepbound, Trulicity, Mounjaro; **Overlap in beneficiaries is possible if beneficiaries switched insurance types over time.
Current pipeline
The current pipeline for GLP-1 RAs is robust with 1,465 clinical trials in various stages. While the majority of these studies focus on T2D, other conditions of interest include CVD, overweight/obesity, T1D, endocrine disorders associated with insulin metabolism.The pipeline for dual RAs, such as GIP/GLP-1 RAs, is much less robust with, only 27 clinical trials in Phase 1–Phase 4. These dual RAs are being evaluated mainly in T2D, T1D, overweight/obesity, and few other possible indications (Figure 2). Manufacturers may expect significant levels of competition, specifically within the GLP-1 RA class, and will need to differentiate their assets and value proposition to remain competitive and maintain and/or grow their market share.
Figure 2. GLP-1 and GIP/GLP-1 RAs pipeline
Source: clinicaltrials.gov
Value differentiation and connection to coverage
New entrants to this crowded market will need to differentiate themselves through a strong payer value story that spans beyond T2D, overweight/obesity, CVD indications. In addition, both new and established manufacturers in this space should consider studying additional indications to further differentiate themselves from current or future competitors. A strong value proposition will have downstream impacts on securing favorable coverage and formulary placement, which will be addressed in our next insight.
Data source
For this analysis, Avalere used commercial and Managed Medicaid claims data from Inovalon’s proprietary “Medical Outcomes Research for Effectiveness and Economics” (MORE2) Registry®, accessed by Avalere via an Agreement with Inovalon, Inc. Avalere also utilized the 100% Medicare FFS claims, accessed by Avalere via a research collaboration with Inovalon, Inc. and governed by a research-focused CMS Data Use Agreement.


